Skip to main content
SpringerLink
Log in

Astellas Pharma Inc has announced that, in the US phase II clinical trial of FG-2216

  • Media release
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Astellas Pharma Inc.Adverse Event of FG-2216 for the Treatment of Anemia. Media Release: 7 May 2007. Available from: URL: http://www.astellas.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Astellas Pharma Inc has announced that, in the US phase II clinical trial of FG-2216. React. Wkly. 1151, 3 (2007). https://doi.org/10.2165/00128415-200711510-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200711510-00007

Keywords

Search

Navigation